Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).

Next Previous
X
Search
Trial Profile

A Phase IIIB, Single Arm Study, of Durvalumab in Combination With Platinum-Etoposide for Untreated Patients With Extensive-Stage Small Cell Lung Cancer Reflecting Real World Clinical Practice in Spain (CANTABRICO).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Registrational
  • Acronyms CANTABRICO
  • Sponsors AstraZeneca

    • Most Recent Events

    • 24 Oct 2023 Results assessing safety and effectiveness of D+EP in a real-world ES-SCLC population in Spain presented at the 48th European Society for Medical Oncology Congress
    • 18 Jul 2023 Status changed from active, no longer recruiting to completed.
    • 04 Jan 2023 Planned End Date changed from 31 Dec 2022 to 30 Jun 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top